Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 2, 2010, Pages 158.e1-158.e40

  Indermaur, Megan D ^a   Xiong, Yin ^a   Kamath, Siddharth G ^a,b   Boren, Todd ^a   Hakam, Ardeshir ^a,b   Wenham, Robert M ^a,b   Apte, Sachin M ^a,b   Lancaster, Johnathan M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

doxorubicin; endometrial cancer; microarray gene analysis; Src pathway; targeted therapy

Indexed keywords

AGRIN; AROMATIC HYDROCARBON RECEPTOR; B LYMPHOCYTE RECEPTOR; BROMINE DERIVATIVE; CD40 ANTIGEN; DEATH RECEPTOR; DIMETHYLTHIAZOLDIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; G PROTEIN COUPLED RECEPTOR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG SENSITIVITY; DRUG SENSITIZATION; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENOMICS; HUMAN; HUMAN CELL; INNATE IMMUNITY; MOLECULAR RECOGNITION; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 77955658811     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.02.003     Document Type: Article

References (16)

1. The American Cancer Society Cancer Facts and Figures 2009 [ACS web site] Available at: http://www.cancer.org/downloads/STT/500809web.pdf Accessed July 15, 2009
2. M.S. Carey, C. Gawlik, M. Fung-Kee-Fung, A. Chambers, and T. Oliver Systemic review of systemic therapy for advanced or recurrent endometrial cancer Gynecol Oncol 101 2006 158 167
3. H.K. Dressman, A. Berchuck, G. Chan, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer J Clin Oncol 25 2007 517 525
4. A. Potti, H.K. Dressman, A. Bild, et al. Genomic signatures to guide the use of chemotherapeutics Nat Med 12 2006 1294 1300
5. A.A. Jazaeri, C.S. Awtrey, G.V. Chandramouli, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers Clin Cancer Res 11 2005 6300 6310
6. A. Bild, G. Yao, J.T. Chang, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies Nature 439 2006 353 357
7. A. Shah, and G. Gallick Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs 18 2007 371 375
8. H. Zeng, K. Datta, M. Neid, J. Li, S. Parangi, and D. Mukhopadhyay Requirement of different signaling pathways mediated by insulin-like growth factor-1 receptor for proliferation, invasion, and VPF/VEGF expression in pancreatic carcinoma cell line Biochem Biophys Res Commun 302 2003 46 55
9. R. Alverez, H. Kantarjian, and J. Cortes The role of Src in solid and hemorrhagic malignancies Development of new-generation Src inhibitors Cancer 107 2006 1918 1929
10. R.B. Irby, W. Mao, D. Coppola, et al. Activating SRC mutations in a subset of advanced human colon cancers Nat Genet 12 1999 187 190
11. M.S. Talamonti, M.S. Roh, S.A. Curley, and G.E. Gallick Increased in activity and level of pp60c-scr in progressive stages of human colorectal cancer J Clin Invest 91 1993 53 60
12. H. Aligayer, D.D. Boyd, M.M. Heiss, E.K. Abdalla, S.A. Curley, and G.E. Gallick Activation of Src kinase pathway in primary colorectal carcinoma: an indicator of poor clinical prognosis Cancer 94 2002 344 351
13. T. Chen, J. George, and C. Taylor Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anticancer Drugs 17 2006 123 131
14. N. Masumoto, S. Nakano, H. Fujishima, K. Kohno, and Y. Niho v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells Int J Cancer 80 1999 731 737
15. M. Duxbury, H. Ito, M. Zinner, S.W. Ashley, and E.E. Whang Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells Clin Cancer Res 10 2004 2307 2318
16. M. Talpaz, N.P. Shah, H. Kantarjian, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2596